The AZI2 (5-azacytidine-induced protein 2), also known as ZKSCAN3. is a zinc finger protein implicated in transcriptional regulation and cellular autophagy processes. It belongs to the SCAN domain-containing family of proteins, which are involved in chromatin remodeling and gene expression modulation. AZI2 functions as a transcription factor that binds to specific DNA sequences, regulating the expression of lysosomal and autophagy-related genes. Research has highlighted its role in maintaining cellular homeostasis, particularly under stress conditions, by balancing autophagic activity and nutrient metabolism. Dysregulation of AZI2 has been associated with cancer progression, immune responses, and neurodegenerative diseases. For instance, it is overexpressed in certain cancers, where it may promote tumor survival by enhancing lysosomal function and drug resistance. The AZI2 antibody is a critical tool for studying these mechanisms, enabling the detection and localization of AZI2 in cells and tissues via techniques like Western blotting, immunofluorescence, and immunohistochemistry. Its application extends to elucidating AZI2’s interaction networks, post-translational modifications, and downstream targets. Recent studies also explore AZI2’s potential as a therapeutic target, particularly in cancers with aberrant autophagy signaling. This antibody thus serves as a vital reagent for dissecting AZI2’s biological roles and its implications in disease pathogenesis.